I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
A multi-center effectiveness comparison study of fruquintin..:
Ying Jin
;
Jin Li
;
Lin Shen
...
https://www.frontiersin.org/articles/10.3389/fonc.2022.1044328/full. , 2022
Link:
https://doi.org/10.3389/fonc.2022.1044328
RT Journal T1
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:4e50d27fb8cf44ccb7590602ac65c18d&Exemplar=1&LAN=DE A1 Ying Jin A1 Jin Li A1 Lin Shen A1 Jianming Xu A1 Yanqiao Zhang A1 Jingdong Zhang A1 Hongming Pan A1 Xiujuan Qu A1 Yamin Chen A1 Qiang Zhang A1 Jinnan Li A1 Miaomiao Sun A1 Shukui Qin PB Frontiers Media S.A. YR 2022 K1 fruquintinib K1 FRESCO K1 real-world data K1 metastatic colorectal cancer K1 tyrosine kinase inhibitors K1 progression free survival K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://www.frontiersin.org/articles/10.3389/fonc.2022.1044328/full LK http://dx.doi.org/https://doi.org/10.3389/fonc.2022.1044328 DO https://doi.org/10.3389/fonc.2022.1044328 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)